Startseite
Märkte
Charts & Ideen
Algo
Nachrichten
Store
Broker
Herunterladen
Wirtschaftskalender
Handelssignale
WebTerminal
Geben Sie
/
ein, um zu suchen: @user, $symbol
Suche
Einloggen
Eröffnen Sie ein Konto
Deutsch
English
Русский
中文
Español
Português
日本語
한국어
Français
Italiano
Türkçe
CLDX
#3995
Celldex Therapeutics, Inc
30.090
0
+0.40%
Sektor:
Basis:
Gewinnwährung:
Tagesspanne
Jahresspanne
Tagesänderung
+0.40%
Monatliche Änderung
+14.80%
6 month change
+10.46%
Jahresänderung
+10.46%
Vorheriger Schlusskurs
29.970
0
Open
30.000
0
Bid
Ask
Low
30.000
0
High
30.090
0
Volumen
102
Märkte
Aktien
Gesundheitswesen
CLDX
Open full chart
Financials
Overview
Finanzbericht
Statistics
Dividends
Quarterly
Annual
Value
2020
2021
2022
2023
2024
2025
TTM
Key stats
Total common shares outstanding
39.61 M
46.74 M
47.21 M
55.9 M
66.38 M
66.57 M
—
Valuation ratios
Enterprise value
650.21 M
1.77 B
2.02 B
2.22 B
1.65 B
1.78 B
5.98 B
Price to earnings ratio
—
-23.56
-18.08
-13.84
-10.31
-6.96
-28.1
Price to sales ratio
—
0.36
0.86
0.28
0.23
1.17
2.21
Price to cash flow ratio
—
0.03
0.02
0.02
0.01
0.01
0.03
Price to book ratio
—
0
0.01
0
0
0
0
Enterprise value to EBITDA ratio
-30.59
-108.09
-91.6
-104.31
-57.79
-45.5
—
Profitability ratios
Return on assets %
0.25
0.16
0.24
0.2
0.13
0.44
0.41
Return on equity %
0.29
0.17
0.26
0.21
0.14
0.49
0.44
Return on invested capital %
483.12
711.84
937.82
1 040.56
1 165.13
2 329.78
—
Gross margin %
97.3
97.85
95.76
95.64
97.15
87.06
400
Operating margin %
854.06
1 531.78
4 889.01
2 245.27
2 778.89
18.6 K
-7.27 M
EBITDA margin %
-286.52
-351.43
-935.09
-309.79
-406.48
-2 530.81
—
Net margin %
805.88
1 516.04
3 616.25
1 331.85
1 462.49
16.75 K
-6.62 M
Liquidity ratios
Quick ratio
—
—
—
—
—
—
—
Current ratio
13.93
24.86
17.07
13.87
18.91
10.49
64.83
Inventory turnover
—
—
—
—
—
—
—
Asset turnover
0.04
0.01
0.01
0.02
0.01
0
0
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
—
1 420.57
2 211.65
2 214.7
2 450.5
3 175.83
3 176.63
EBIT per share
—
-452.83
-531.82
-502.2
-492.46
-639.56
—
EBITDA per share
—
-381.27
-470.06
-440.11
-443.12
-588.68
—
Total debt per share
—
—
—
—
—
—
—
Cash per share
—
9 522.98
6 503.84
8 743.17
11.26 K
7 807.25
36.22 K
Net current asset value per share
—
9 583.37
6 775.57
8 910.26
11.6 K
8 049.5
37.37 K
Tangible book value per share
—
9 150.59
6 377.2
8 296.99
11.18 K
7 527.25
35.77 K
Working capital per share
—
9 197.83
6 378.67
8 267.83
10.99 K
7 281.82
34.92 K
Book value per share
—
9 784.84
6 957.09
8 858.2
11.6 K
7 936.6
37.41 K
Nachrichten
Celldex: Positive Phase-2-Daten für Urtikaria-Therapie treiben Aktie an
Celldex presents phase 2 data for chronic urticaria treatment
Celldex Therapeutics Stock Earns 88 RS Rating
Celldex Therapeutics: EPS verfehlt Schätzungen um 0,21 $ - Umsatz schlechter als erwartet
Celldex Therapeutics earnings missed by $0.21, revenue fell short of estimates
Celldex Therapeutics-Aktie erreicht 52-Wochen-Hoch bei 30,66 USD
Celldex Therapeutics stock hits 52-week high at 30.66 USD
Stifel reiterates Celldex Therapeutics stock rating on trial progress
Celldex schließt Rekrutierung für Phase-3-Studie zu chronischer Urtikaria vorzeitig ab
Celldex completes Phase 3 enrollment for CSU treatment ahead of schedule
Celldex: Cantor Fitzgerald bestätigt ’Overweight’-Rating und Kursziel von 67 $
Celldex stock rating reiterated as Overweight by Cantor Fitzgerald